Program
antihemophilic factor, human recombinant
Also written as “Antihemophilic factor, recombinant, manufactured protein-free”, “Recombinant Factor VIII (BAY81-8973)” and “ADVATE”.
Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 3 companies.
Drug pageAntihemophilic factor, human recombinant: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 101 open or running | phase 4since Oct 21, 2005 | Sep 8, 2005 | Nov 25, 2027phase 3 · NCT07129343 |
| Bayerits history only | 50 open or running | phase 4since Sep 4, 2020 | Dec 8, 2009 | none ahead |
| Novo Nordisk | 10 open or running | phase 1since Feb 4, 2009 | Feb 4, 2009 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas and Baxter Innovations.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novo Nordisk only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 4, 2009First study: phase 1 study in Hemophilia AFirst studyNCT00837356 · 23 enrolled · Germany, Israel, Italy and more
TargetBeta
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule
Other programs on F8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efanesoctocog alfarule | Sanofi | phase 4 | 12 |
| omfiloctocog alfarule | Sinocelltech Group | phase 4 | 6 |
| lonoctocog alfarule | CSL | phase 3 | 4 |
Studies
The one study Novo Nordisk leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00837356Hemophilia A · Germany, Israel, Italy and more | 1 | Completed | Oct 2009 | 23 |
How it is read
Names in the registry
- “Antihemophilic factor, recombinant, manufactured protein-free”, 8 entries
- “Recombinant Factor VIII (BAY81-8973)”, 3 entries
- “ADVATE”, 2 entries
- “Recombinant Factor VIII (Kovaltry, BAY81-8973)”, 2 entries
- “Antihemophilic Factor (Recombinant)”, 1 entry
Codes read as this program: BAY818973.
Conditions, from the studies’ own filings
- Hemophilia A, 14 studies
- von Willebrand Diseases, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.